|
Sign In to gain access to subscriptions and/or personal tools.
|
Secretory Leukocyte Protease Inhibitor (SLPI): Oxidation of SLPI Does Not Explain Its Variable Anti-HIV Activity
K. Konopka
Department of Microbiology, School of Dentistry, University of the Pacific, 2155 Webster Street, San Francisco, California 941 15.2399), USA
N. Shine
Department of Microbiology, School of Dentistry, University of the Pacific, 2155 Webster Street, San Francisco, California 941 15.2399), USA
E. Pretzer
Department of Microbiology, School of Dentistry, University of the Pacific, 2155 Webster Street, San Francisco, California 941 15.2399), USA, Lynx Thera peutics, 3832 Bay Center Place, Hayward, California 94545, USA
N. Düzgünes
Department of Microbiology, School of Dentistry, University of the Pacific, 2155 Webster Street, San Francisco, California 941 15.2399), USA
Secretory leuhocyte protease inhibitor (SLPI) has been proposed as a potential inhibitor of HIV-1 infection in human saliva. Although the ability of recombinant (r) SLPI to inhibit HIV-1 infection of macrophages and primary T-cells has been demonstrated by two independent laboratories, evidence to the contrary has also been reported. This study re-examines the anti-HIV effect of rSLPI and investigates the effects of repeated freeze-thawing and oxidation on the anti-HIV activity of rSLPI. rSLPI inhibited HIV-1 BaL infection of human macrophages in a highly variable manner. HPLC and electrospray ionization mass spectrometry (ESI) analyses indicated that variability in our inhibition data could not be attributed to the degradation or oxidation of rSLPI. These results suggest that the variable anti-HIV effect of rSLPI may be due to differential expression of the cell-surface molecule(s) to which SLPI binds rather than to changes in the rSLPI molecule.
Key Words: HIV-1 • saliva • SLPI • macrophages.
REFERENCES
- Berger EA (1997). HIV entry and tropism: the chemokine receptor connection. AIDS 11(Suppl A):S3-S16.[Medline]
[Order article via Infotrieve]
- Boudier C., Bieth JG (1994). Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor. Biochem J 303:61-68.[Medline]
[Order article via Infotrieve]
- Coffey MJ, Woffendin C., Phare SM, Strieter RM, Markovitz DM (1997). RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am J Physiol 272:L1025-L1029.
- Dragic T., Litwin V., Allaway GP, Martin SR, Huang Y., Nagashima KA, et al. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.[CrossRef][Medline]
[Order article via Infotrieve]
- Konopka K., Davis BR, Larsen CE, Alford DR, Debs RJ, Düzgünes N. (1990). Liposomes modulate human immunodeficiency virus infectivity. J Gen Virol 71:2899-2907.[Abstract/Free Full Text]
- Konopka K., Pretzer E., Felgner PL, Düzgünes N. (1996). Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim Biophys Acta 1312:186-196.[Medline]
[Order article via Infotrieve]
- Konopka K., Shine NR, Pretzer E., Düzgünes N. (1997). Inhibition of HIV infection by secretory leukocyte protease inhibitor (abstract). J Dent Res 76:220.
- McNeely TB, Dealy M., Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM ( 1995). Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 96:456-464.[Medline]
[Order article via Infotrieve]
- McNeely TB, Shugars DC, Rosendahl M., Tucker C., Eisenberg SP, Wahl SM ( 1997). Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90:1141-1149.[Abstract/Free Full Text]
- Moriuchi M., Moriuchi H., Combadiere C., Murphy PM, Fauci AS (1996). CD8+ T-cell-derived soluble factor(s), but not β-chemokines RANTES, MIP-1
 , and MIP-1β, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA 93:15341-15345.[Abstract/Free Full Text] - Naif HM, Li S., Alali M., Sloane A., Wu L., Kelly M., et al. (1998). CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 72:830-836.[Abstract/Free Full Text]
- Pretzer E., Flasher D., Düzgüne
 N. (1997). Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease. Antiviral Res 34:1-15.[CrossRef][Medline]
[Order article via Infotrieve] - Rich EA, Chen IS, Zack JA, Leonard ML, O'Brien WA (1992). Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest 89:176-183.[Medline]
[Order article via Infotrieve]
- Schmidtmayerova H., Sherry B., Bukrinsky M. (1996). Chemokines and HIV replication. Nature 382:767.[CrossRef][Medline]
[Order article via Infotrieve]
- Shine N., Konopka K., Düzgüne N. (1997). The anti-HIV-1 activity associated with saliva. J Dent Res 76:634-640.
- Shugars DC, McNeely TB, Eisenberg S., Wahl SM ( 1996). Secretory leukocyte protease inhibitor targets an early event in HIV infection (abstract). J Dent Res 75:114.
- Shugars DC, Sauls DL, Weinberg JB (1997). Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1. Oral Dis 3(Suppl 1):S70-S72.
- Turpin JA, Schaeffer CA, Bu M., Graham L., Buckheit RW Jr, Clanton D., et al. (1996). Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor. Antiviral Res 29:269-277.[CrossRef][Medline]
[Order article via Infotrieve]
Journal of Dental Research, Vol. 78, No. 12,
1773-1776 (1999)
DOI: 10.1177/00220345990780120201
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. H. Kazmi, J. R. Naglik, S. P. Sweet, R. W. Evans, S. O'Shea, J. E. Banatvala, and S. J. Challacombe
Comparison of Human Immunodeficiency Virus Type 1-Specific Inhibitory Activities in Saliva and Other Human Mucosal Fluids
Clin. Vaccine Immunol.,
October 1, 2006;
13(10):
1111 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Jana, L. R. Gray, and D. C. Shugars
Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity
J. Virol.,
May 15, 2005;
79(10):
6432 - 6440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Doumas, A. Kolokotronis, and P. Stefanopoulos
Anti-Inflammatory and Antimicrobial Roles of Secretory Leukocyte Protease Inhibitor
Infect. Immun.,
March 1, 2005;
73(3):
1271 - 1274.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Geiben-Lynn, N. Brown, B. D. Walker, and A. D. Luster
Purification of a Modified Form of Bovine Antithrombin III as an HIV-1 CD8+ T-cell Antiviral Factor
J. Biol. Chem.,
October 25, 2002;
277(44):
42352 - 42357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
